SyncVR Medical · GTM Brief · CULT+MATH
April 2026 · Confidential
SyncVR Medical · Pre-Discovery GTM Brief
The door you're
knocking on is
the wrong door.
Floris, you've built the largest VR healthcare platform in Europe. You have 250+ hospitals, 14 clinical trials, and evidence that actually moves. The US market doesn't know any of that — not because your product isn't ready, but because you're talking to the wrong people first.
→
How to use this brief: Read it as a provocation, not a prescription. I made assumptions — some of them are probably wrong. What I need from you is one conversation where you tell me what I got wrong. That conversation is the point.
01 — The Situation
You have a distribution problem,
not a product problem.
SyncVR is revenue-driven and self-funded. That discipline is a superpower. It also means your US entry has to be surgical — you cannot afford to knock on every door in American healthcare. The good news: you don't have to. You have to find the one door that, once opened, pulls all the others open behind it.
Going to doctors and nurses first is the instinct. It's also the slowest, most expensive path in the US healthcare system. Clinicians adopt technology when demand pulls them toward it — not when a sales rep pushes from the outside. The question isn't "how do we convince clinicians?" It's "who creates the demand that makes clinicians ask for this themselves?"
250+
European hospitals on platform
14
Clinical trials validating the evidence
93%
Reduction in pain medication needed with VR
02 — The GTM Thesis
Two moves. One beachhead.
Every successful US healthcare technology entry that didn't have $50M to spend on enterprise sales found a wedge — one specific use case, one specific audience, one specific procedure — and owned it completely before expanding. These are your two moves.
Move 1 — The Demand Engine
Win parents.
Not clinicians.
A parent who watches their terrified child go calm inside a VR headset becomes your most powerful distribution channel — and it costs you nothing. They tell every parent in their network. They ask the hospital to make it standard. They post about it. They name-check the technology by name in parent Facebook groups that have 40,000 members. Parents don't need to understand the clinical evidence. They need to see their child's face change.
Move 2 — The Beachhead Procedure
Own one procedure
before owning a hospital.
Pediatric IV placement and blood draws happen thousands of times per month in every children's hospital in America. The fear is universal. The before-and-after is dramatic and visible. Every clinician in the building witnesses it. Every parent remembers it. Win this one procedure deeply — get the data, get the story, get the staff champion — then use that as the key to every other door in the hospital. KindVR, your closest US competitor, built their first 75 hospital relationships exactly this way.
The Core Thesis
"The moment a child puts on the headset, the sale is already made — you just haven't invoiced it yet."
The most powerful GTM asset SyncVR has is not your clinical evidence, your platform, or your 250 European hospitals. It is the moment itself — the moment a scared child goes somewhere else entirely, and the parent standing next to them exhales for the first time. That moment travels. It gets shared. It creates demand that no sales team can manufacture. Your entire US GTM strategy should be organized around producing that moment as many times as possible, in as concentrated a geography as possible, and then letting the parents and the staff carry it forward.
03 — Competitive Landscape
What the US market
currently sounds like.
Here is the first thing every US competitor says to a hospital buyer — the words a decision-maker sees before they've read anything else. The white space is clear.
KindVR — Closest competitor
"We make it easy for hospitals to provide clinically validated VR therapy to every patient in need."
75+ US pediatric hospitals. Procedure-specific focus. Unfunded, small team. Their weakness: narrow app library, no platform breadth. SyncVR's platform depth is a genuine differentiator they cannot match.
AppliedVR — $68.7M raised
"FDA-cleared VR therapeutics for chronic pain."
Adult chronic pain, not pediatric. FDA-prescription model. Not competing for the same patient in the same moment. Different lane entirely.
Xploro — UK-based pediatric
"Making medical therapy less daunting for young patients through gamification."
Education and preparation, not procedural distraction. Complementary, not directly competing. Potentially a partnership candidate.
SyncVR — Your current US voice
"Immersive Care, Simplified & Scaled."
Platform language. Enterprise language. The right message for a hospital IT director — wrong message for a parent advocate, a child life specialist, or a pediatric nurse who needs to believe before they'll champion. The voice needs a US-specific layer.
The white space nobody is occupying: There is no VR healthcare company in the US talking directly to parents — as the primary audience, in their language, about their child's experience. Every competitor is talking to the hospital. You could be the first to talk to the family. That is your differentiation.
04 — What I Need to Know
Tell me what
I got wrong.
This brief is a starting hypothesis, not a finished strategy. There are three things I genuinely don't know that would change the entire direction of this work. The conversation I'm asking for is specifically to answer these.
The Three Questions
01
When a hospital in Europe finally adopted — what broke the log jam? Was it a clinician champion, a parent story, an administrator chasing satisfaction scores, or something else entirely?
This tells me which lever actually works and where to apply it first in the US.
02
What specific procedures or departments are you targeting in the US right now — and why those?
This tells me whether the beachhead thesis is already your instinct, or whether I'm off on the entry point.
03
What keeps you up at night about the US entry that no one outside the company knows about?
The answer to this is the brief. Whatever word you use to describe it is the word the strategy is built around.
05 — One Ask
Before you close this
I'd like 30 minutes — a call or a coffee — to hear what this brief got wrong. Not to pitch. Not to sell. CULT+MATH's job is to make your narrative as precise as your platform. I think there's something here worth developing together. If you agree, let's find time this week.